Weight-loss medications containing semaglutide or tirzepatide, such as Wegovy, Ozempic, and Mounjaro, are increasingly linked by early research and patient accounts to a notable reduction in alcohol consumption, driven by changes in the brain’s reward response that suppress cravings and alter physical tolerance. According to Dr Christian Hendershot of the University of South Carolina, these GLP-1 receptor agonists mimic a natural hormone to keep people feeling fuller for longer while also dampening the desire for substances like alcohol and nicotine.
Clinical Research Links GLP-1 Medications to Reduced Heavy Drinking
Clinical studies are beginning to substantiate what patients have reported anecdotally about weight-loss drugs curbing their desire to drink. Dr Christian Hendershot published a small-scale study in 2025 showing that participants with alcohol use disorder experienced fewer alcohol cravings while taking Ozempic. Building on this, a study from the University of Colorado Anschutz published last week indicated that pill-form GLP-1 medications led to fewer days of heavy drinking in people with mild to moderate alcohol use disorder. Despite these promising findings, researchers like Dr Joseph Schacht note that larger, longer-term studies are required before regulators can approve these drugs for the treatment of alcohol use disorder.
Patient Experiences Show Divided Impact on Social Lives
For some users, the dampening effect on alcohol serves as an unexpected health bonus, while others find it creates social hurdles. Lisa Rees, a 46-year-old from South Wales taking Wegovy, reported to BBC News that she now stops after a couple of glasses of wine because she physically cannot drink another drop, cutting her weekly consumption from between six and eight bottles down to a fraction of that. Similarly, Warren Thomas, a 45-year-old from Colchester taking Mounjaro, stated that his tolerance level to drinking is now zero. Conversely, 20-year-old Faye Goodwin told BBC Your Voice that rapid nausea and acid reflux from drinking while on Mounjaro have complicated her university social life in Cambridge, occasionally forcing her to delay her jab by a day to manage social outings.
Did you know? While drugs like Wegovy, Mounjaro and Ozempic, contain semaglutide or tirzepatide, some facilities in the US are already prescribing the medication off-label to people with alcohol use disorder, according to Dr Christian Hendershot.
According to Prof Russell Hearn, a GP and professor of medicine at King's College London, there is currently no formal advice in the British National Formulary regarding whether people on weight-loss drugs should stop drinking alcohol, though reducing intake will definitely help with weight loss goals. Meanwhile, Dr Darren Quelch, who researches addiction at the University of South Wales, points out that critical questions remain regarding safety for people without obesity and diabetes, affordability, and potential side effects like rare but serious pancreatitis, even as researchers are also looking into whether GLP-1 medications could be a treatment for other addictions, including smoking and opioids.
Frequently Asked Questions
Do weight-loss drugs completely stop alcohol cravings for everyone?
No. While clinical studies and patient accounts show a reduction in cravings for many users, others report no noticeable effect on their relationship with alcohol.
Are Wegovy and Ozempic officially approved to treat alcoholism?
Not yet. According to clinical researchers, larger and longer-term studies are necessary before it can be approved by regulators for the treatment of alcohol use disorder.
What are the primary physical reasons for drinking less on GLP-1 medications?
Patients report that the drugs affect the reward response in the brain, induce quick satiety or nausea, and dramatically lower their physical alcohol tolerance after just one or two drinks.
What are your thoughts on the secondary effects of weight-loss medications? Share your experiences in the comments below, subscribe to our newsletter for ongoing health updates, and explore our latest health coverage for more in-depth reporting.